XBiotech

IGM Biosciences halts development of imvotamab and IGM-2644 due to disappointing Phase I results, leading to a 73% workforce reduction. The company, with $183.8M in cash, seeks alternative cost recovery methods. Stock dropped 70%. Denali Therapeutics and XBiotech also face trial setbacks.

XBiotech halts its rheumatological disease clinical program after its Phase II Rheumatoid Arthritis study failed to meet its primary endpoint due to irregularities. The study, involving Natrunix and methotrexate, showed discrepancies in data analysis, prompting further evaluation before proceeding with additional studies.

Pomerantz LLP investigates XBiotech Inc. for potential securities fraud after its stock price dropped due to pausing a phase 2 rheumatoid arthritis program. Investors are advised to contact Danielle Peyton for class action information.

XBiotech halts rheumatology studies after Natrunix Phase II trial fails, citing irregularities. Stock drops 27%. Follow-up studies on arthritis and ankylosing spondylitis postponed indefinitely.

XBiotech suspended its rheumatology program after its Phase II study of Natrunix for Rheumatoid Arthritis failed to meet the ACR20 response rate primary endpoint and revealed significant irregularities, including multiple enrollments of the same subjects at high-enrolling sites. Planned studies in arthritis and ankylosing spondylitis are now on hold.